CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights
Summary
and ROSTOCK, Germany and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (we or the Company), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided a business update.In 2023, we focused on strategic growth strengthening our Diagnostic portfolio and introducing new data and wet lab solutions to accelerate drug discovery, development, and commercialization for Pharma. CENTOGENE to remain active in Lifera Omics operations to deliver genomic and multiomic testing None Initiated strategic alternatives process focused on sustainable long-term value creation for the benefit of its stakeholders None Expanded the CENTOGENE Biodatabank to over 850,000 patients, over 70% of whom are of non- European descent, approximately 30,000 active physicians, and more than 85 million unique variants thanks to the increasing number of CentoXome\xae and CentoGenome\xae analyses, which contain significantly more variants than more targeted diagnostic tests None Authored over 30 peer-reviewed scientific publications in FY2023, reaching a milestone of over 300 publications in the Companys history. Starting off Q1 2024, the Company has formed collaborations with eight new partners None Extended Takeda partnership to March 2026 to continue providing access to genetic testing for patients with lysosomal storage disorders None Announced research project with The Michael J. Seamlessly integrating with CentoCloud\xae, CENTOGENEs CE-marked Software as a Service (SaaS) bioinformatics pipeline, FilterTool is one of the first applications to receive CE mark under new In Vitro Diagnostic Regulation (IVDR) from the European Parliament None Launched together with TWIST Bioscience three Next Generation Sequencing target enrichment panels, Twist Alliance CNTG Exome, Twist Alliance CNTG Rare Disease Panel, and Twist Alliance CNTG Hereditary Oncology Panel, to support rare disease and hereditary cancer research and support diagnostics None Integrated Illuminas new NovaSeq X Plus Sequencer into the Companys state-of-the-art, CAP/CLIA accredited laboratory in Rostock, Germany, to further optimize throughput, scale, and cost efficiencies None Published research in Science in collaboration with the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine on human pre-T cell receptor alpha (pre-TCR) deficiency and its effect on human immunity None Published study in the European Journal of Human Genetics revealing unique genetic variants in worlds largest Niemann-Pick type C1 disease cohort None Published the discovery of a new form of early-onset dystonia and parkinsonism in the context of neurodevelopmental abnormalities associated to the gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) as part of an international team of researchers. We do not intend to disclose further developments on this strategic review process unless and until we determine that such disclosure is appropriate or necessary.CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.